Navigation Links
Heptares and UK Medical Research Council Extend GPCR Collaboration
Date:6/19/2012

WELWYN GARDEN CITY, England, and BOSTON, June 19, 2012 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, has extended its collaboration with the UK Medical Research Council (MRC), including its leading research groups at the MRC Laboratory of Molecular Biology (LMB, Cambridge, UK) and MRC National Institute of Medical Research (NIMR, London, UK), on the structure and active conformations of G-protein coupled receptors (GPCRs), and other transmembrane proteins. Building upon their existing relationship with the MRC, and in particular the group led by Chris Tate at the MRC LMB - an internationally recognised expert in structural biology of integral membrane proteins - Heptares will own certain IP and technology in the field, including that pertaining to agonist-induced GPCR states responsible for cell signalling, a key area for drug design.

"Our collaboration with the MRC over the past five years has increased our fundamental understanding of GPCR structure and function tremendously," said Malcolm Weir, CEO of Heptares Therapeutics. "Applying this knowledge has enabled Heptares to establish a leadership position in GPCR-targeted drug discovery and to create a structure-based discovery platform capable of addressing one of the most important but challenging target families. Continuing this relationship with MRC will ensure Heptares remains at the forefront of GPCR research and we are very pleased to continue working together."

Dave Tapolczay, CEO of MRC Technology, the MRC's technology transfer agent, said, "This collaboration between the MRC and Heptares is a great example of how world-class UK science can be developed in a commercial environment. The MRC has been responsible for some of the most important scientific discoveries of the past century, and it is exciting to see this collaboration developing into a real success story."

Heptares was founded in 2007 based on the pioneering research into GPCR stabilisation and structure carried out at the MRC LMB and NIMR. Since then, the Company has greatly advanced, streamlined and integrated this technology to create a powerful structure-based drug discovery platform that is enabling the generation of novel drug candidates that are potent and highly selective for important, yet previously poorly drugged or undruggable, GPCRs. The potential of this platform has also been recognized by pharmaceutical companies seeking to unlock the potential of GPCRs, enabling the Company to sign drug discovery deals with companies including AstraZeneca, MedImmune, Shire and Takeda.

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases.  The company has licensed its first drug candidate to Shire, established R&D collaborations with Takeda, AstraZeneca and MedImmune, and raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.  Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically undruggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, autism, anxiety & depression, chronic insomnia, addiction and diabetes.  For more information, please visit http://www.heptares.com.

About the Medical Research Council

For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century.

http://www.mrc.ac.uk  

About MRC Technology

MRC Technology is a technology transfer company responsible for translating cutting edge scientific discoveries into commercial products.  MRC Technology adds value to cutting edge scientific discoveries through strategic patent protection and creative licensing of intellectual property (IP), through partnered research or through further scientific development. MRC Technology also has small molecule drug discovery and therapeutic antibody facilities, providing lead stage therapeutic assets to pharmaceutical and biotechnology companies.

http://www.mrctechnology.org  


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Medical Device Developers - Network at BIOMEDevice Boston Next Week
3. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
8. Essential Medical Dismisses Patent Case against Masimo and Cercacor
9. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
10. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
11. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... 2016 , ... Research has shown that building shame resilience ... and level of relapse. , At the 2016 iaedp Symposium, the ... the critical tasks of the recovery phase and beyond including relapse prevention and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... City, UT (PRWEB) , ... February 05, 2016 , ... ... Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in ... Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
Breaking Medicine News(10 mins):